By Colin Kellaher
Arcturus Therapeutics Holdings has won U.S. Food and Drug Administration fast-track designation for its ARCT-2304 pandemic flu vaccine candidate.
Arcturus on Thursday said the designation recognizes the potential of ARCT-2304, a messenger RNA-based vaccine candidate, to address unmet medical needs for the prevention of disease caused by pandemic influenza A virus H5N1.
The FDA's fast-track program is designed to facilitate the development and expedite the review of treatments for serious or potentially life-threatening illnesses with high unmet medical needs.
Arcturus, a San Diego medicines and vaccines company, in November launched a Phase 1 clinical study, supported in whole with federal funds from the Department of Health and Human Services.
Outbreaks of avian influenza A H5N1, also known as bird flu, have been decimating U.S. poultry flocks since 2022, and while the federal government currently assesses the risk from H5N1 viruses to the general U.S. population as low, it has committed hundreds of millions of dollars to push development of vaccines for a potential pandemic.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 10, 2025 08:44 ET (12:44 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。